Halozyme Therapeutics
HALO
Dorian LPG
LPG
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
Teradata Corp
TDC
Hutchmed (China)
HCM
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -32.85%27.38M | 35.15%32.19M | -63.47%6.15M | 169.14%108.35M | 66.32%26.92M | 215.48%40.77M | 26.08%23.82M | 317.28%16.84M | 769.11%40.26M | 155.09%16.19M |
Net income from continuing operations | -58.45%8.08M | -32.29%18.81M | 8.93%15.87M | 40.13%73.83M | -14.27%12.04M | 17.53%19.45M | 63.02%27.78M | 187.76%14.57M | 112.28%52.69M | 75.32%14.04M |
Operating gains losses | 521.19%1.63M | 106.52%292K | -425.13%-647K | 7.10%-1.74M | 1,255.56%2.93M | 77.46%-387K | -5,234.52%-4.48M | 168.86%199K | 70.70%-1.87M | -61.08%216K |
Depreciation and amortization | 7.23%3.64M | 3.12%3.44M | 13.84%3.68M | -10.44%13.31M | 2.79%3.35M | 3.13%3.39M | -16.94%3.34M | -24.76%3.24M | -11.85%14.86M | -25.03%3.26M |
Deferred tax | -37.94%-2.44M | 37.02%-1.25M | -47.41%-1.68M | 15.72%-3.87M | 96.92%1.02M | 17.78%-1.77M | 20.80%-1.99M | -152.11%-1.14M | -1,141.72%-4.59M | -8.14%519K |
Other non cash items | -103.82%-24K | 145.56%724K | -109.04%-45K | -181.69%-1M | -164.91%-542K | 132.96%629K | -3,775.61%-1.59M | 201.82%498K | -52.33%1.23M | 1,997.73%835K |
Change In working capital | -16.73%15.48M | 5,306.78%9.22M | -725.37%-11.84M | 199.59%24.34M | 316.93%7.36M | 576.50%18.59M | -470.97%-177K | 91.62%-1.44M | 32.07%-24.44M | 55.57%-3.39M |
-Change in receivables | -29.56%6.16M | 82.11%5.32M | 135.02%4.37M | 361.93%27.95M | 92.48%14.43M | 183.53%8.74M | 133.48%2.92M | 81.37%1.86M | 60.66%-10.67M | 689.85%7.5M |
-Change in inventory | -72.89%4.29M | -60.76%2.28M | -25.67%5.69M | 191.86%33.61M | 207.02%4.3M | 317.28%15.84M | 165.11%5.82M | 146.82%7.65M | -7.61%-36.59M | 64.04%-4.02M |
-Change in payables and accrued expense | 145.59%4.28M | 178.09%5.09M | -329.41%-20.3M | -211.30%-23.59M | -2,933.51%-11.32M | -208.78%-9.38M | -89.38%1.83M | -10.32%-4.73M | -21.54%21.2M | -110.98%-373K |
-Change in other current assets | ---- | ---- | ---- | -52.44%2.75M | ---- | ---- | ---- | ---- | 269.20%5.79M | ---- |
-Change in other current liabilities | ---- | ---- | ---- | -293.75%-16.39M | ---- | ---- | ---- | ---- | -366.79%-4.16M | ---- |
-Change in other working capital | -77.73%756K | 67.63%-3.48M | 74.22%-1.6M | ---- | ---- | -35.04%3.4M | -2,728.61%-10.75M | -349.76%-6.22M | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -32.85%27.38M | 35.15%32.19M | -63.47%6.15M | 169.14%108.35M | 66.32%26.92M | 215.48%40.77M | 26.08%23.82M | 317.28%16.84M | 769.11%40.26M | 155.09%16.19M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 669.71%25.38M | -246.29%-10.38M | -13.64%-15.58M | -664.89%-53.54M | -1,218.70%-42.46M | -1,291.88%-4.45M | 570.92%7.09M | -602.05%-13.71M | 62.93%-7M | 37.62%-3.22M |
Net PPE purchase and sale | -50.00%-3.62M | -169.27%-1.31M | 26.74%-2.74M | 12.99%-6.09M | 43.04%-1.83M | -654.38%-2.41M | 225.76%1.89M | -91.30%-3.74M | -238.61%-7M | 37.62%-3.22M |
Net business purchase and sale | --0 | --0 | --0 | ---5.22M | ---307K | ---135K | --5.2M | ---9.98M | --0 | --0 |
Net investment purchase and sale | --29.28M | ---8.92M | ---12.35M | ---40.07M | ---40.07M | --0 | --0 | --0 | --0 | ---- |
Net other investing changes | ---285K | ---141K | ---492K | ---2.15M | ---247K | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 669.71%25.38M | -246.29%-10.38M | -13.64%-15.58M | -664.89%-53.54M | -1,218.70%-42.46M | -1,291.88%-4.45M | 570.92%7.09M | -602.05%-13.71M | 62.93%-7M | 37.62%-3.22M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -263.10%-3.02M | 78.62%-8.73M | -270.70%-7.12M | -81.53%-38.6M | 93.06%-1.11M | 74.97%-832K | -3,383.70%-40.83M | 606.80%4.17M | -153.12%-21.26M | -1,610.62%-15.94M |
Net issuance payments of debt | --0 | --0 | --0 | -100.00%-35M | --0 | --0 | ---40M | --5M | -302.67%-17.5M | ---15M |
Net common stock issuance | ---1.88M | ---7.89M | ---6.28M | 69.91%-105K | ---105K | --0 | --0 | --0 | ---349K | --0 |
Cash dividends paid | 2.28%-813K | -0.97%-837K | -0.97%-837K | -2.31%-3.49M | -6.26%-1M | -0.97%-832K | -0.73%-829K | -0.73%-829K | -1.01%-3.41M | -1.18%-943K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -263.10%-3.02M | 78.62%-8.73M | -270.70%-7.12M | -81.53%-38.6M | 93.06%-1.11M | 74.97%-832K | -3,383.70%-40.83M | 606.80%4.17M | -153.12%-21.26M | -1,610.62%-15.94M |
Net cash flow | ||||||||||
Beginning cash position | 30.63%84.98M | -8.38%71.32M | 27.19%89.37M | 13.78%70.27M | 41.37%100.23M | -1.18%65.05M | 51.93%77.84M | 13.78%70.27M | -27.29%61.76M | 14.42%70.9M |
Current changes in cash | 40.15%49.73M | 232.01%13.09M | -326.88%-16.55M | 35.19%16.22M | -459.50%-16.65M | 282.40%35.48M | -161.15%-9.92M | 169.32%7.3M | 152.97%12M | -1,280.56%-2.98M |
Effect of exchange rate changes | -41.48%-440K | 119.71%566K | -637.63%-1.5M | 182.85%2.89M | 146.85%5.79M | 92.62%-311K | -77.11%-2.87M | 9,200.00%279K | -549.16%-3.49M | 613.35%2.35M |
End cash Position | 33.96%134.27M | 30.63%84.98M | -8.38%71.32M | 27.19%89.37M | 27.19%89.37M | 41.37%100.23M | -1.18%65.05M | 51.93%77.84M | 13.78%70.27M | 13.78%70.27M |
Free cash flow | -37.82%23.75M | 50.46%30.85M | -75.36%3.22M | 206.20%96.22M | 88.60%24.46M | 251.76%38.19M | 17.90%20.5M | 233.57%13.07M | 759.50%31.43M | 1,075.70%12.97M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |